Multiple Myeloma Survival Nearly Doubles Over 15 Years Despite Remaining Incurable
核心洞察
Median survival for multiple myeloma (搜索) patients in England has increased from 2.4 years to 4.5 years between 2005 and 2019, representing nearly a doubling of survival time.
The study analyzed 3,720 patients and found the most dramatic improvement in patients aged 80 and over, with five-year survival rates rising five-fold since 2005.
Despite these advances, experts emphasize that survival remains "devastatingly low" and call for improved clinical trial access and continued research investment.
Patients with multiple myeloma (搜索), an incurable blood cancer (搜索), are now living nearly twice as long as they did two decades ago, according to a comprehensive study analyzing real-world survival data from England. The research, published in Haematologica and funded by Cancer Research UK and Blood Cancer UK, demonstrates significant therapeutic progress while highlighting persistent challenges in treating this devastating disease.
Dramatic Survival Improvements Documented
Researchers at the University of York (搜索) analyzed data from 3,720 patients diagnosed with multiple myeloma (搜索) between 2005 and 2019, revealing that median survival increased from 2.4 years to 4.5 years over the 15-year period. The researchers described this improvement as "impressive" and confirmed "that therapeutic advances are benefiting patients not only in clinical trials, but in the real-world setting."
Multiple myeloma (搜索) occurs when bone marrow produces abnormal white blood cells called plasma cells (搜索). The disease presents with symptoms including bone pain, fatigue, headaches, muscle weakness, and shortness of breath. Approximately 6,200 cases are diagnosed annually in the UK, equivalent to 17 new diagnoses daily.
Elderly Patients Show Most Significant Gains
The study revealed particularly striking improvements among older patients. Survival increased most dramatically in patients aged 80 and over, with the number of people in this age group living for five years or more rising five-fold since 2005. Researchers attribute this progress to better tolerated treatments for older patients and emphasized "the importance of not excluding older and frailer patients from clinical trials."
Alexandra Smith, professor of cancer epidemiology at the University of York (搜索) and lead author of the study, explained the significance of these advances: "Thanks to research, someone diagnosed with myeloma now has far better prospects than they would have two decades ago. New treatments are kinder, less toxic, and more effective, allowing every patient – including the most vulnerable – to benefit."
Persistent Challenges Demand Continued Innovation
Despite the encouraging survival trends, experts stressed that multiple myeloma (搜索) remains a formidable challenge. Smith cautioned: "But we can't stop here. Survival for myeloma remains devastatingly low – which is why continued research into new ways to treat the disease, and diagnose it sooner, is so vital."
Dr. Richard Francis, deputy director of research at Blood Cancer UK, provided additional context on the disease burden: "Blood cancer (搜索) is the UK's third biggest cancer killer and too many people with myeloma still die far too soon." He emphasized that while "these results show that research works," continued progress requires "world-class blood cancer research," "faster access to clinical trials," and "an NHS that can get the best new treatments to patients quickly."
Clinical Trial Access Remains Critical Barrier
The study highlighted ongoing disparities in clinical trial access as a significant obstacle to further progress. Francis noted that "clinical trials offer real hope, but too often blood cancer (搜索) patients struggle to access them." He called for "a system that makes it easier for people with blood cancer from all backgrounds to take part, alongside increased investment in myeloma clinical trials."
Michelle Mitchell, chief executive of Cancer Research UK, reinforced the importance of research infrastructure: "Every improvement in cancer survival represents invaluable time for patients to spend with the people they love. This progress is testament to the hard work of both scientists and NHS staff, showing the importance of putting research at the front and centre of our health service."
The findings underscore both the remarkable progress achieved in multiple myeloma (搜索) treatment over the past two decades and the urgent need for continued research investment and improved clinical trial accessibility to further extend survival for patients facing this incurable disease.